RGS:ASX

Regeneus Ltd.

Regeneus Ltd. is a clinical-stage regenerative medicine company developing a patented portfolio of therapies to address significant unmet medical needs in the human and veterinary health markets. The company has four therapies targeting human conditions in various stages of development including two products approved for first-in-human Phase 1 trials: Progenza is an allogeneic off-the-shelf adipose stem cell therapy to treat osteoarthritis and other musculoskeletal conditions; RGSH4K is a human autologous personalized therapeutic cancer vaccine to treat a wide range of cancer types. Furthermore, Regeneus is developing therapies to target acne and other inflammatory skin conditions in humans, in addition to musculoskeletal and oncology treatments for animals.
RGS:ASX

Expert Comments:

Dennis Hulme, Edison Investment Research (12/8/16)
"Regeneus Ltd. is developing and commercializing its adipose-derived mesenchymal stem cell technology for musculoskeletal conditions in animals and humans. . .Recent Japanese legislation offers an accelerated path to market for regenerative medicine products and the company is currently working to finalise manufacturing and clinical development partnerships in Japan. Regeneus also holds global rights to autologous cancer vaccine technologies for human (RGSH4K - Phase I began in Q215) and veterinary (Kvax) applications. . .cancer immunotherapy, including cancer vaccines such as RGSH4K, is a biotech hotspot."

Dennis Hulme, Edison Investment Research (11/17/16)
"Regeneus Ltd. is developing and commercializing its adipose-derived mesenchymal stem cell technology for musculoskeletal conditions in animals and humans. . .recent Japanese legislation offers an accelerated path to market for regenerative medicine products and the company is currently working to finalize manufacturing and clinical development partnerships in Japan. Regeneus also holds global rights to autologous cancer vaccine technologies for human and veterinary (Kvax) applications. . .Regeneus has firmed up its strategy to partner its product opportunities for development and commercialization, allowing it to focus on early-stage product development. It has partnered with a top-5 global animal health company."

Maxim Jacobs, Edison Investment Research (10/20/16)
"Regeneus Ltd. announced the completion of enrollment of all 20 patients in the STEP randomized Phase I/II study of Progenza in human osteoarthritis, and confirmed no safety concerns had been identified. . .Japanese legislation offers an accelerated path to market for regenerative medicine products and the company is currently working to finalize manufacturing and clinical development partnerships in Japan. Regeneus also holds global rights to autologous cancer vaccine technologies for human and veterinary (Kvax) applications. . .Regeneus has firmed up its strategy to partner its product opportunities for development and commercialization, allowing it to focus on early-stage product development."

Australian regenerative medicine company Regeneus Ltd. has a handful of stock-moving Q4/16 catalysts on the calendar, among them a potential licensing agreement for its mesenchymal stem cell technology in Japan.
read more >
Edison Investment Research (9/22/16)
"Regeneus Ltd. is developing and commercialising its adipose-derived mesenchymal stem cell technology for musculoskeletal conditions in animals and humans. . .recent Japanese legislation offers an accelerated path to market for regenerative medicine products and the company aims to finalise manufacturing and clinical development partnerships in Japan in Q316. Regeneus also holds global rights to autologous cancer vaccine technologies for human and veterinary applications. . .Regeneus has firmed up its strategy to partner its product opportunities for development and commercialisation, allowing it to focus on early-stage product development."

The Australian government has bolstered Regeneus, a regenerative medicine company targeting cancer, osteoarthritis and other musculoskeletal conditions, with $2.73 million in funding.
read more >
Dennis Hulme, Edison Investment Research (9/14/16)
"Regeneus Ltd. anticipates entering a binding arrangement with a manufacturing and commercialisation partner for its Progenza mesenchymal stem cell therapy technology in Japan by the end of the current quarter. . .Directors expect the company to receive upfront funding and milestone payments on entering this agreement. . .Progenza is the key long-term value driver, with peak sales estimated at A$1.75bn. . .The company's second product in development for human clinical applications is its RGSH4K human therapeutic cancer vaccine. Recruitment is anticipated to be completed in Q4 CY16 in the ACTIVATE Phase I trial."

Dennis Hulme, Edison Investment Research (8/18/16)
"Regeneus Ltd. is developing and commercialising its adipose-derived mesenchymal stem cell technology for musculoskeletal conditions in animals and humans. . .Japanese legislation offers an accelerated path to market for regenerative medicine products and the company aims to finalise manufacturing and clinical development partnerships in Japan in Q316. Regeneus also holds global rights to autologous cancer vaccine technologies for human (RGSH4K - Phase I began in Q215) and veterinary (Kvax) applications. . .Regeneus has firmed up its strategy to partner its product opportunities for development and commercialisation. . .cancer immunotherapy, including cancer vaccines such as RGSH4K, is a biotech hotspot."

More Expert Comments

Experts Following This Company

Katherine Genis, Analyst – Edison Investment Research
Dennis Hulme, Analyst – Edison Investment Research
Maxim Jacobs – Edison Investment Research
Marcel Wijma, Analyst – The Daily Molecule (Van Leeuwenhoeck Research), Van Leeuwenhoeck Research

The information provided above is from analysts, newsletters, the company and other contributors.

Regeneus Ltd. is a sponsor of Streetwise Reports. The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.

Investing Highlights
 
RGS entered into a strategic collaboration and licensing agreement with AGC Asahi Glass (AGC) for the exclusive manufacture of Progenza in Japan
 
Patented portfolio of personalized and off-the-shelf cell therapies for human and veterinary markets.
 
Veterinary products CryoShot Canine and Kvax are in advanced clinical stage and ready for partnering
 
Progenza and RGSH4K are in first-in-human clinical trials
catalyst Calendar